Literature DB >> 19240814

Transplantation for type 1 diabetes mellitus. Whole organ or islets?

D Vrochides1, St Paraskevas, V Papanikolaou.   

Abstract

Two types of transplants are offered to patients with complicated insulin dependent diabetes mellitus: a) whole pancreas transplantation, b) pancreatic islet transplantation. A total of 29000 whole pancreas transplantations and 1500 islet transplantations have been performed worldwide until today. Patient survival for whole pancreas recipients is 85% five years after transplantation, whereas very few islet studies focus on patient survival. Graft survival for whole pancreas recipients is 90%, 70% and 45%, at one, five and ten years after transplantation respectively. On the other hand, only 44% of islet recipients are still insulin free, one year after engraftment. If the definition of a successful islet transplantation is not insulin independence but production of C-peptide, then 80% of the same islet recipients have a functioning graft by the end of the first post-transplant year. It is a known fact that whole pancreas transplantation has significant complications. The most common complications after whole organ transplantation include technical failures, acute rejection and CMV infection, whereas islet transplantation is associated with portal vein thrombosis, bleeding, emergency exploratory laparotomy, liver steatosis and rapamune-induced mouth ulcers. The cumulative cost of a whole organ transplantation is about ?40,000. On the other hand, the cumulative cost of a pancreatic islet transplant is estimated to be higher than ?120,000. Whole organ transplantation halts the late complications of diabetes, namely vasculopathy, retinopathy, nephropathy and neuropathy. Although similar claims are made for islet transplantation, its impact on long-term diabetic complications is possible but not proven. Currently, in North America, lean young donors are utilized for whole organ transplants, whereas overweight or older donors are utilized for islet transplants. In conclusion, although islet transplantation is an extremely promising therapy and probably the way of the future, whole organ transplant is still the gold standard according to evidence-based medicine.

Entities:  

Keywords:  diabetes; islets; pancreas; transplantation

Year:  2009        PMID: 19240814      PMCID: PMC2633258     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  20 in total

1.  Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone.

Authors:  Massimo Venturini; Paolo Fiorina; Paola Maffi; Claudio Losio; Andrea Vergani; Antonio Secchi; Alessandro Del Maschio
Journal:  Transplantation       Date:  2006-05-15       Impact factor: 4.939

2.  Changes in renal function after clinical islet transplantation: four-year observational study.

Authors:  P A Senior; M Zeman; B W Paty; E A Ryan; A M James Shapiro
Journal:  Am J Transplant       Date:  2007-01       Impact factor: 8.086

Review 3.  Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004.

Authors:  Angelika C Gruessner; David E R Sutherland
Journal:  Clin Transplant       Date:  2005-08       Impact factor: 2.863

4.  Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients.

Authors:  Paolo Fiorina; Chiara Gremizzi; Paola Maffi; Rossana Caldara; Davide Tavano; Lucilla Monti; Carlo Socci; Franco Folli; Ferruccio Fazio; Ettore Astorri; Alessandro Del Maschio; Antonio Secchi
Journal:  Diabetes Care       Date:  2005-06       Impact factor: 19.112

5.  Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes.

Authors:  Michael R Rickels; Mark H Schutta; Rebecca Mueller; James F Markmann; Clyde F Barker; Ali Naji; Karen L Teff
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

6.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

Authors:  A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

7.  International trial of the Edmonton protocol for islet transplantation.

Authors:  A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

8.  Five-year follow-up after clinical islet transplantation.

Authors:  Edmond A Ryan; Breay W Paty; Peter A Senior; David Bigam; Eman Alfadhli; Norman M Kneteman; Jonathan R T Lakey; A M James Shapiro
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

Review 9.  The clinical impact of islet transplantation.

Authors:  P Fiorina; A M J Shapiro; C Ricordi; A Secchi
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

10.  Islet cell transplantation today.

Authors:  Reinhard G Bretzel; Henning Jahr; Michael Eckhard; Isabel Martin; Daniel Winter; Mathias D Brendel
Journal:  Langenbecks Arch Surg       Date:  2007-03-28       Impact factor: 2.895

View more
  6 in total

1.  Reversal of diabetes in mice with a bioengineered islet implant incorporating a type I collagen hydrogel and sustained release of vascular endothelial growth factor.

Authors:  Robert B Vernon; Anton Preisinger; Michel D Gooden; Leonard A D'Amico; Betty B Yue; Paul L Bollyky; Christian S Kuhr; Thomas R Hefty; Gerald T Nepom; John A Gebe
Journal:  Cell Transplant       Date:  2012       Impact factor: 4.064

Review 2.  Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3.

Authors:  Talitha van der Meulen; Mark O Huising
Journal:  Rev Diabet Stud       Date:  2014-05-10

Review 3.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

Review 4.  Imaging pancreatic islet cells by positron emission tomography.

Authors:  Junfeng Li; Johann Karunananthan; Bradley Pelham; Fouad Kandeel
Journal:  World J Radiol       Date:  2016-09-28

Review 5.  The Future of Islet Transplantation Is Now.

Authors:  Rita Bottino; Michael F Knoll; Carmela A Knoll; Suzanne Bertera; Massimo M Trucco
Journal:  Front Med (Lausanne)       Date:  2018-07-13

Review 6.  Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes.

Authors:  Meghan Tahbaz; Eiji Yoshihara
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-10       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.